Page last updated: 2024-09-04

atrasentan and carboplatin

atrasentan has been researched along with carboplatin in 1 studies

Compound Research Comparison

Studies
(atrasentan)
Trials
(atrasentan)
Recent Studies (post-2010)
(atrasentan)
Studies
(carboplatin)
Trials
(carboplatin)
Recent Studies (post-2010) (carboplatin)
3584110812,8954,0015,244

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antonia, S; Bepler, G; Boulware, D; Burton, M; Chiappori, AA; Haura, E; Kapoor, R; Lush, R; Neuger, AM; Padilla, B; Rodriguez, FA; Simon, G; Sullivan, DM; Williams, C1

Trials

1 trial(s) available for atrasentan and carboplatin

ArticleYear
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-01, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelin A Receptor Antagonists; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Pyrrolidines; Survival Rate

2008